Article
The FDA granted tentative approval to generic versions of two popular urology drugs, one for BPH and the other for overactive bladder.
Desai Sethi Urology Institute shares inaugural Annual Report
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Call for Abstract, Workshop, and Roundtable Submissions for PFD Week 2025
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
Take Charge of 2025: A Financial Webinar Series for Physicians
FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer